insights_auto
Pse është rritur EVO 3,14%?
Zhytu më thellëchevron_right
EVO:NASDAQ
Evotec SE
1,64Â US$
arrow_upward
+3,14%(+0,050) 1D
1,64Â US$
0,00% (0,00)
bedtimeJashtë orarit
Mbyllur: 29 sht, 4:00:01 m.d., GMT-4 · USD
search
Të gjitha simbolet
1D
5D
1M
6M
YTD
1V
5V
Maks
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për EVO...
Hap
1,60Â US$
I lartë
1,64Â US$
I ulët
1,60Â US$
Kapitalizimi i tregut
596,72Â mln
Vëllimi mesatar
118,06 mijë
Vëllimi
94,94 mijë
Maksimumi 52-javor
4,27Â US$
Minimumi 52-javor
1,50Â US$
Fitimet për aksion
-0,63Â US$
Beta
1,92
Aksionet në qarkullim
355,82Â mln
Numri i punonjësve
4 mijë
Hap
1,60Â US$
I lartë
1,64Â US$
I ulët
1,60Â US$
Kapitalizimi i tregut
596,72Â mln
Vëllimi mesatar
118,06 mijë
Vëllimi
94,94 mijë
Maksimumi 52-javor
4,27Â US$
Minimumi 52-javor
1,50Â US$
Fitimet për aksion
-0,63Â US$
Beta
1,92
Aksionet në qarkullim
355,82Â mln
Numri i punonjësve
4 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
TipRanks
·
13 orë më parë
Evotec SE Announces Chief Scientific Officer Transition as Long-Serving CSO Steps Down
AD HOC NEWS
·
14 orë më parë
Evotec stock gains 2.45 percent as chief scientist exits
Stock Titan
·
17 orë më parë
After 16 years, Evotec's science chief is stepping down
Profili
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Rreth Evotec SE
Drejtori ekzekutiv-
Punonjësit4,46 mijë
Themeluar më1993
Selia-
SektoriHealth care
Uebsajtievotec.com